Description
Benlysta (belimumab) is a medication used to treat systemic lupus erythematosus (SLE), a long-term autoimmune disorder that can affect the skin, joints, and internal organs. Benlysta is a type of biologic drug, which is derived from living cells, and is administered through intravenous infusion by a healthcare provider.
Uses:
Benlysta is used to treat adult patients with active, autoantibody-positive SLE who are receiving standard therapy. It is not approved for use in patients with severe active lupus nephritis or severe active central nervous system lupus.
Storage Conditions:
Benlysta should be stored at room temperature between 68°F and 77°F (20°C and 25°C). It should not be frozen or shaken, and must be protected from light. The medication should be used within 4 hours of dilution, and any unused portion should be discarded.
Mechanism of Action:
Benlysta works by inhibiting the activity of B-lymphocyte stimulator (BLyS or BAFF), a protein that plays a role in the production of antibodies by B cells in the immune system. By preventing the activation and survival of these cells, Benlysta reduces inflammation associated with SLE.
How to Use:
Benlysta is administered by intravenous infusion, usually in a healthcare setting. The dosage, frequency, and duration of treatment are determined by the healthcare provider based on the patient’s weight, medical history, and response to therapy.
Precautions:
Before receiving Benlysta, patients should inform their healthcare provider of any allergies, medical conditions, and medications they are currently taking. Benlysta may cause adverse reactions, including infusion reactions, infections, and depression. Patients with certain medical conditions, such as infections or recent vaccinations, may not be able to receive the drug.
Drug Interactions:
Benlysta may interact with other medications, including immunosuppressive agents, which may increase the risk of infection. Patients should inform their healthcare provider of any medications they are taking before beginning treatment with Benlysta.
Contraindications:
Benlysta is contraindicated in patients with severe allergic reactions to the medication or any of its components.
Overdose:
In the event of an overdose, healthcare providers should monitor patients for symptoms and provide supportive care as needed.
Adverse Reactions:
The most common adverse reactions reported with Benlysta include infusion reactions, infections, and depression. Other adverse reactions may include fever, headache, nausea, and diarrhea. Patients should report any adverse reactions to their healthcare provider immediately.
Overall, Benlysta is a biologic medication used to treat SLE by inhibiting the activity of BLyS, reducing inflammation in the immune system. It is administered by intravenous infusion in a healthcare setting, and the dosage and duration of treatment are determined by the healthcare provider. Patients should inform their healthcare provider of any allergies, medical conditions, and medications they are currently taking. Benlysta may cause adverse reactions, such as infusion reactions, infections, and depression. Patients with certain medical conditions may not be able to receive the drug.
Reviews
There are no reviews yet.